Brendan  Luu net worth and biography

Brendan Luu Biography and Net Worth

Mr. Luu joined Enanta in January 2021. Prior to Enanta, he was at Merck KGaA, where he held roles of increasing responsibility. Most recently, he was Vice President and Global Head of Oncology Business Development, responsible for setting the franchise business development strategy and was accountable for its execution, including the completion of several major transactions across all stages of drug development in line with the company’s R&D goals. Previously, Mr. Luu was Senior Director and Global Head of Business Development, Strategic Initiatives, where he led the strategy and partnering efforts to secure external financing for Merck KGaA’s late-stage pipeline. Before that, he was Director, Global Licensing and Business Development, Neurology and Immunology, where he led in/out licensing transactions for preclinical and clinical-stage assets to support R&D in neurodegenerative diseases. Previously, he was an Associate Director of Regional Business Development, General Medicines responsible for growing the product portfolio in the Asia-Pacific region. Earlier in his career, he held various roles in the chemicals industry with BASF Corporation and in telecommunications with Tyco International, working in engineering, sales and marketing.

Mr. Luu graduated magna cum laude from Drexel University with a B.S. in Chemical Engineering and Biology. He holds an M.B.A from the New York University Stern School of Business.

What is Brendan Luu's net worth?

The estimated net worth of Brendan Luu is at least $527.14 thousand as of December 5th, 2025. Luu owns 38,329 shares of Enanta Pharmaceuticals stock worth more than $527,139 as of April 28th. This net worth estimate does not reflect any other assets that Luu may own. Learn More about Brendan Luu's net worth.

How do I contact Brendan Luu?

The corporate mailing address for Luu and other Enanta Pharmaceuticals executives is 500 ARSENAL STREET, WATERTOWN MA, 02472. Enanta Pharmaceuticals can also be reached via phone at (617) 607-0800 and via email at [email protected]. Learn More on Brendan Luu's contact information.

Has Brendan Luu been buying or selling shares of Enanta Pharmaceuticals?

Brendan Luu has not been actively trading shares of Enanta Pharmaceuticals over the course of the past ninety days. Most recently, Brendan Luu sold 1,394 shares of the business's stock in a transaction on Friday, December 5th. The shares were sold at an average price of $14.23, for a transaction totalling $19,836.62. Following the completion of the sale, the insider now directly owns 38,329 shares of the company's stock, valued at $545,421.67. Learn More on Brendan Luu's trading history.

Who are Enanta Pharmaceuticals' active insiders?

Enanta Pharmaceuticals' insider roster includes Nathalie Adda (VP), Kathleen Capps (Insider), Tara Kieffer (Insider), Jay Luly (CEO), Brendan Luu (Insider), Paul Mellett, Jr. (Sr. VP of Fin. & Admin. and CFO ), Yat Or (Insider), and Scott Rottinghaus (Insider). Learn More on Enanta Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Enanta Pharmaceuticals?

During the last year, insiders at the biotechnology company sold shares 7 times. They sold a total of 11,961 shares worth more than $170,149.14. The most recent insider tranaction occured on December, 5th when insider Kathleen S Capps sold 323 shares worth more than $4,596.29. Insiders at Enanta Pharmaceuticals own 11.5% of the company. Learn More about insider trades at Enanta Pharmaceuticals.

Information on this page was last updated on 12/5/2025.

Brendan Luu Insider Trading History at Enanta Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/5/2025Sell1,394$14.23$19,836.6238,329View SEC Filing Icon  
12/5/2023Sell2,125$9.63$20,463.7536,736View SEC Filing Icon  
See Full Table

Brendan Luu Buying and Selling Activity at Enanta Pharmaceuticals

This chart shows Brendan Luu's buying and selling at Enanta Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Enanta Pharmaceuticals Company Overview

Enanta Pharmaceuticals logo
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: $13.71
Low: $13.26
High: $13.78

50 Day Range

MA: $13.55
Low: $12.08
High: $15.41

2 Week Range

Now: $13.71
Low: $4.96
High: $17.15

Volume

102,662 shs

Average Volume

182,022 shs

Market Capitalization

$397.86 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.99